News Image

Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Growth Momentum and Technical Setup

By Mill Chart

Last update: Oct 16, 2025

Investors looking for high-growth momentum chances often search for companies showing strong earnings speed-up, positive estimate changes, and growing profit margins. The ChartMill High Growth Momentum Rating methodically assesses these elements, merging them into one number to find stocks with outstanding growth features. When this momentum rating is combined with strong technical condition and a clear setup pattern, as shown by ChartMill's Technical Rating and Setup Quality scores, it forms a persuasive investment case. This method helps locate securities that not only display fundamental growth momentum but also offer good entry points from a technical viewpoint.

TVTX Stock Chart

Growth Momentum Fundamentals

Travere Therapeutics Inc (NASDAQ:TVTX) receives a High Growth Momentum Rating of 6, showing good growth features in several areas. The company's recent results display notable speed-up in both earnings and revenue, with special force in quarterly comparisons:

  • Quarterly EPS growth rates: 84.6% (current quarter), 73.3% (previous quarter), 29.1% (two quarters prior)
  • Quarterly revenue growth rates: 111.5% (current quarter), 97.5% (previous quarter), 66.0% (two quarters prior)
  • Full-year revenue growth is at 87.9% on a trailing twelve-month basis
  • Free cash flow has gotten better by 45.4% over the past year

The company has shown steady skill to beat forecasts, exceeding revenue estimates in three of the last four quarters by an average of 4.9% and EPS estimates in two of the last four quarters by an average of 10.1%. While analyst changes for next year's EPS have been negative, revenue estimates for the coming year have been changed upward by 5.9% over the past three months, showing ongoing belief in the company's growth path.

Technical Strength and Market Position

Travere Therapeutics shows very good technical condition with a Technical Rating of 9, putting it in the group of top-performing stocks from a technical viewpoint. The stock shows force across several time periods with both short-term and long-term trends clearly positive. Important technical features include:

  • The stock trades in the higher part of its 52-week range ($12.91 - $28.69)
  • All main moving averages (20, 50, 100, and 200-day) are going up
  • Relative strength of 92.6 shows the stock is doing better than most of the market
  • Strong results over several periods: +13.5% (1-month), +66.7% (3-month), +80.0% (6-month)

The stock's technical picture is especially remarkable given the present market situation where the S&P 500 shows a neutral long-term trend but positive short-term momentum. Travere's skill to keep strong upward momentum in this setting highlights its technical force.

Setup Quality and Trading Considerations

With a Setup Rating of 7, Travere presents a workable consolidation pattern that may give a possible entry chance. The technical study points to lower volatility while prices have been consolidating in the recent period, with very little resistance above current price levels. The setup is further backed by interest from big players in recent days, as measured by the Effective Volume indicator.

The technical report finds several support levels that could give downside protection:

  • Immediate support at $23.90 from a horizontal line
  • Secondary support at $20.50 from a daily trend line
  • More support levels at $16.87, $15.16, and $14.50 from different trend lines and horizontal supports

For traders thinking about a position, the detailed technical analysis suggests a possible entry above $27.22 with a stop loss below $23.83, representing a measured risk of about 12.4%. This setup joins the stock's strong technical base with a clear risk management method.

Investment Implications

Travere Therapeutics stands as an interesting case where strong fundamental growth momentum lines up with good technical features. The company's speeding-up revenue growth, especially in recent quarters, joined with getting-better earnings trends and positive cash flow progress, creates a persuasive growth story. From a technical viewpoint, the stock's strong rating and clear setup pattern give a structure for possible entry points.

The joining of these factors—growth momentum, technical force, and setup quality—makes Travere worth thinking about for investors using high-growth momentum plans. The methodical way of screening for stocks that rate well across these several aspects helps find chances that might otherwise be missed in wider market study.

For investors wanting to find similar chances, more screening results can be found through the High Growth Momentum Breakout Setups Screen, which regularly updates with stocks meeting these conditions.

Disclaimer: This analysis is for informational purposes only and does not constitute investment advice, recommendation, or endorsement of any security. Investors should conduct their own research and consult with a qualified financial advisor before making investment decisions. Past performance is not indicative of future results, and all investments carry risk including potential loss of principal.

TRAVERE THERAPEUTICS INC

NASDAQ:TVTX (10/21/2025, 10:24:04 AM)

27.5

-0.39 (-1.4%)



Find more stocks in the Stock Screener

TVTX Latest News and Analysis

Follow ChartMill for more